Toni Choueiri: Exciting advances in prostate cancer treatment at ASCO24!
Petros Grivas shared a post by Toni Choueiri, on X:
“Promising data by Dr. Morris on novel anti-hK2 targeted agent in mCRPC! Interesting mechanism with durable responses but ILD and low PLT were dose limiting. ”
Quoting Toni Choueiri‘s post:
“Exciting advances in prostate cancer treatment at ASCO24!
JNJ-6420, a novel anti-hK2 Ab-based targeted radiotherapy, shows promising results in heavily pretreated mCRPC patients.
Despite notable adverse events, profound and durable responses were observed at ≥150 μCi doses.”
Source: Petros Grivas/X and Toni Choueiri/X
Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.
Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).
He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA.
Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.
